Abstract: The invention relates to an assistance terminal (5, 6a, 6b) including a housing (5) and at least one terminal (6a, 6b) for remotely monitoring a person (1) connected to a medical assistance and/or monitoring device (3).

Abstract: The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.

Abstract: The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia.

Abstract: The present invention relates to a method for the determination of a nucleic acid sequence by physical manipulation. The method is based on the precise determination of the localization of the replicating fork on the template by measuring the physical distance between one end of the molecule and the fork. This allows the determination of the physical location of the site where a pause or a blockage of the replication occurs, and deducing therefrom information on the sequence of the nucleic acid.

Abstract: The present invention relates to a nucleic acid molecule containing a sequence of tricyclo nucleosides joined by internucleoside phosphorothioate linkage. The invention also relates to synthetic antisense oligonucleotides and to methods employing the same.

Abstract: The present invention relates to a fast method for the detection and the quantification of a nucleic acid, DNA or RNA. Specifically, the invention provides a method for detecting and quantifying the presence of a specific nucleic acid molecule which is based on physical and electronic treatments. The method of the invention is particularly useful for applications as diverse as detection of chromosomal abnormal distributions or gene expression analysis.

Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.

Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.

Abstract: The present invention relates to compounds, capable of activating HIV expression in reservoir cells, of formula (I) for use in the treatment of HIV infection.

Abstract: The invention relates to an optical device for measuring the position of an object along a first axis, the object being subjected to light radiations emitted by a light source.

Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Abstract: A system for treating at least one sensory capacity of a person with the help of a stimulation device comprises an electronic converter of a sensory signal into an electronic signal for controlling at least one transducer for emitting signals that are images of the sensory signal. The stimulation device for direct ultrasound stimulation of the sensory cortex of a brain comprises at least one support that is implantable in a skull and that includes at least one internal wall and at least one ultrasound transducer carried by the support. Means for emitting focused ultrasound waves through the internal wall of the support towards a determined zone of the sensory cortex of the patient's brain in order to generate modulation of the brain activity in the cortex are provided. The ultrasound transducer is driven by the electronic converter to emit focused ultrasound signals that are images of the sensory signal.

Abstract: The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Abstract: The present invention relates to novel fluoroquinolones, pharmaceutical compositions or medicament containing them and use thereof to treat bacterial infection.

Abstract: The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitro cell proliferation and for treatment of various diseases.

Abstract: A vector that includes a cell-penetrating peptide linked to a therapeutic agent. The therapeutic agent can be a cytotoxic agent, an anti-viral agent, an anti-bacterial agent, or an anti-parasitic agent.

Abstract: A method of 3D reconstruction of a scene, including the implementation of at least two sensors each having a series of elementary receivers arranged so as to view the scene according to distinct respective solid angles and which are each sensitive to a physical characteristic of a signal received by the receiver originating from the scene. The sensors are adapted for emitting an asynchronous stream of events indicative of a modification of the signal received by one of the elementary receivers at a given instant, as well as the implementation of a 3D reconstruction algorithm having a step of pairing elementary receivers of each of the sensors utilizing signals generated by the sensors, the pairing including pairing between them events generated by each of the sensors and temporarily close together.

Abstract: The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 ?m (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.

Abstract: Provided herein are methods for expressing a polynucleotide of interest in the retina of a subject. In particular, a method for expressing a polynucleotide of interest in the retina of a subject comprising the step consisting of injecting into the vitreous an amount of a vector containing the polynucleotide of interest in combination with an amount of an inhibitor of Dp71 expression is provided.

Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.